CRISPR Therapeutics AG (CRSP)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: Switzerland
Exchange: NASDAQ
Market cap: $5.47B
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Latest financial period: June 30, 2026
Filed with the SEC: August 3, 2026
Estimated earnings date: November 9, 2026
Profit #1345 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 7.1% | 6.5% | 6.5% | 8.3% |
Growth #1431 of 1484 companies
Payout #1117 of 1484 companies
Safety #897 of 1484 companies
Price #1441 of 1484 companies
